RemeGen (HKG:9995, SHA:688331) has completed its share repurchase plan after buying back 194,144 of its China-listed shares for about 20 million yuan, according to a Wednesday Hong Kong bourse filing.

The biopharmaceutical company repurchased the shares on Jan. 20 through centralized bidding at prices ranging from 102.17 yuan to 103.78 yuan per share. The repurchased shares represented about 0.03% of its total issued share capital.

The buyback reached the lower end of the approved repurchase amount of 20 million yuan to 40 million yuan, bringing the repurchase plan to completion, the company said.

The repurchased shares will be held in a dedicated securities account and are intended for future employee stock ownership plans or equity incentives, the filing showed.